Last reviewed · How we verify
Twice-daily combination Darunavir and ritonavir
Twice-daily combination Darunavir and ritonavir is a Small molecule drug developed by Ruth M. Rothstein CORE Center. It is currently FDA-approved. Also known as: Prezista and norvir twice-daily.
The twice-daily combination of Darunavir and ritonavir, marketed by the Ruth M. Rothstein CORE Center, holds a position in the HIV treatment market. A key strength is the extended patent protection until 2028, which helps maintain market exclusivity. The primary risk is the lack of specified revenue data, which may impact financial forecasting and investment decisions.
At a glance
| Generic name | Twice-daily combination Darunavir and ritonavir |
|---|---|
| Also known as | Prezista and norvir twice-daily |
| Sponsor | Ruth M. Rothstein CORE Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV (PHASE1, PHASE2)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- B-free Multistage Trial (PHASE4)
- HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (PHASE1)
- DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects (PHASE4)
- TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Twice-daily combination Darunavir and ritonavir CI brief — competitive landscape report
- Twice-daily combination Darunavir and ritonavir updates RSS · CI watch RSS
- Ruth M. Rothstein CORE Center portfolio CI
Frequently asked questions about Twice-daily combination Darunavir and ritonavir
What is Twice-daily combination Darunavir and ritonavir?
Who makes Twice-daily combination Darunavir and ritonavir?
Is Twice-daily combination Darunavir and ritonavir also known as anything else?
What development phase is Twice-daily combination Darunavir and ritonavir in?
Related
- Manufacturer: Ruth M. Rothstein CORE Center — full pipeline
- Also known as: Prezista and norvir twice-daily
- Compare: Twice-daily combination Darunavir and ritonavir vs similar drugs
- Pricing: Twice-daily combination Darunavir and ritonavir cost, discount & access